Id: acc0530
Group: 1sens
Protein: AMPK
Gene Symbol: PRKAA1
Protein Id: Q13131
Protein Name: AAPK1_HUMAN
PTM: phosphorylation
Site: Thr183
Site Sequence: MMSDGEFLRTSCGSPNYAAPE
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype:
Disease Cellline: MIA PaCa-2
Disease Info:
Drug: Met + 2-Deoxy-d-glucose
Drug Info: "Met: - 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism by targeting hexokinase, thereby suppressing glycolysis and cellular energy production."
Effect: modulate
Effect Info: The combined treatment of 2DG and Met further enhanced the phosphorylation of AMPK and GFAT1 and significantly reduced the viability of two pancreatic cancer cell lines.
Note: drug comb
Score: 4.0
Pubmed(PMID): 29753740
Sentence Index:
Sentence:

Sequence & Structure:

MRRLSSWRKMATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVVGKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRRLFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLNPSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCEKFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTRPHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIKQLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTATPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEMCANLIKILAQ

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
PRKAA1 ACADESINE AMP-activated protein kinase, AMPK activator 3 - cardiovascular disease ATC
PRKAA1 ACADESINE AMP-activated protein kinase, AMPK activator 1 Completed chronic lymphocytic leukemia ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
PRKAA1-Thr183
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 183 D Colon cancer/carcinoma Phosphorylation 25679763
T 183 U Breast cancer Phosphorylation 30413706

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: